RBC Capital Reiterates Outperform on Legend Biotech, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev reiterates an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintains an $85 price target.

March 07, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and an $85 price target on Legend Biotech.
The reiteration of an Outperform rating and maintenance of an $85 price target by a reputable analyst like Leonid Timashev from RBC Capital is likely to instill confidence among investors and could positively influence Legend Biotech's stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100